Innate's KIR royale

With a product on the market that harnesses the adaptive immune system to attack cancer, Bristol-Myers Squibb Co. made its first move into the innate immunology space by licensing a mAb from Innate Pharma S.A. that stimulates NK cell activity.

The candidate, IPH 2102, is in a Phase I trial for acute myelogenous leukemia...